Related by context. All words. (Click for frequent words.) 74 CSBMs 72 CSBM 71 SBMs 70 SBM frequency 68 oxycodone CR 68 #mg/day [001] 68 abdominal pain abdominal discomfort 67 gout flares 66 non menstrual pelvic 66 Index CDAI 66 incontinence episodes 66 timepoint 66 tapentadol ER 66 #mg/day [002] 66 PASI scores 66 CIMZIA TM 65 nocturnal awakenings 65 desvenlafaxine succinate 65 NPH insulin 65 HBeAg seroconversion 65 lopinavir r arm 65 plus methotrexate 65 mg BID 65 tolterodine ER 65 LANTUS R 65 #mg BID [003] 64 4mg/kg 64 Montgomery Asberg Depression 64 dosing cohorts 64 insulin detemir 64 mcg BID 64 mcg QD 64 GERD symptom 64 mg QD 64 CIMZIA ™ 64 lopinavir r 64 oral rivaroxaban 64 intravitreal injections 63 mg TID 63 morphometric vertebral fractures 63 PREZISTA r 63 IV bolus 63 corticosteroid dose 63 MoxDuo TM IR 63 virologic response 63 #mg BID [001] 63 LEXIVA r 63 headache nasopharyngitis 63 aminotransferase elevations greater 63 acid regurgitation 63 OAB symptoms 63 bloating abdominal pain 63 ritonavir boosted 63 weekly CSBMs 63 HAM D# 62 mg subcutaneously 62 Crohn Disease Activity 62 salmeterol fluticasone 62 detemir 62 certolizumab 62 serum phosphorous 62 CDAI 62 zolmitriptan 62 SVR# 62 APTIVUS r 62 8mg/kg 62 budesonide pMDI 62 achieved statistical significance 62 nausea photophobia 62 solifenacin 62 adjunctive placebo 62 urinary incontinence episodes 62 Psoriasis Area 62 oral antidiabetic medication 62 CIMZIA TM certolizumab pegol 62 dosage regimens 62 tipranavir r 62 achieved ACR# 62 Secondary endpoints included 61 pruritus itching 61 active comparator 61 interferon ribavirin 61 mcg doses 61 apnea hypopnea index 61 TEAEs 61 sustained virologic response 61 Inventory BPI 61 nasal symptom 61 postoperative inflammation 61 IELT 61 BoNTA 61 diarrhea nausea fatigue 61 mesalamine granules 61 hypoglycemic events 61 aromatase inhibitor therapy 61 CCyR 61 timepoints 61 telaprevir dosing 61 mcg kg 61 serum urate 61 statin monotherapy 61 ACTEMRA TM 61 peginterferon alfa 2a 61 AGILECT R 61 Apidra ® 61 HAQ DI 61 moderate renal impairment 61 dose titration 61 placebo dexamethasone 61 mucosal healing 61 ropivacaine 61 RLAI 61 subcutaneous enoxaparin 61 constipation nausea 61 Secondary efficacy endpoints 61 EDARBI 61 partial remissions 61 dyspareunia 61 sUA 60 unresectable HCC 60 MADRS score 60 demonstrated clinically meaningful 60 nasal symptoms 60 undetectable HBV DNA 60 dosing interval 60 serum HCV RNA 60 mg RDEA# 60 administered subcutaneously 60 nadolol 60 amoxicillin clavulanate 60 KAPIDEX 60 vasomotor symptoms 60 ribavirin USP 60 primidone 60 evaluable subjects 60 #mg dose [003] 60 steroid dexamethasone 60 undetectable HCV RNA 60 ALT flares 60 Primary endpoints 60 urate lowering therapy 60 #.#mg/dL 60 ketorolac 60 lumbar spine BMD 60 ug kg 60 PROMACTA 60 mg administered orally 60 comparator arm 60 prospectively stratified 60 inflammatory lesions 60 mesalazine 60 IBS C 60 severe exacerbations 60 FOLPI 60 detectable HCV RNA 60 telaprevir dosed 60 urinary N telopeptide 60 nodular partial response 60 #mg QD [001] 60 FFNS 60 subcutaneous injections 60 Postoperatively 60 analgesic efficacy 60 tamsulosin 60 nighttime awakenings 60 oral alendronate 60 retinal thickness 60 Elitek 60 chills fever headache 60 posttreatment 60 symptom severity 60 SSRI SNRI 60 ACR# [002] 60 receiving XGEVA 60 ARCALYST ® 60 #.#/#.# mmHg [001] 60 certolizumab pegol 60 cytogenetic response 60 cough wheezing 60 ARCOXIA 60 mcg Albuferon 60 postoperative nausea 60 mg/m2 dose 60 generalized edema 60 Secondary endpoints include 60 Raptiva r 60 headache nausea diarrhea 60 extrapyramidal symptoms 60 virologic breakthrough 60 urine albumin 60 pyridostigmine 60 oxycodone IR 60 trials RCTs 60 HCV RESPOND 2 60 intravenous dosing 60 vaginal progesterone gel 60 alfa 2a 60 RLS symptoms 59 fluticasone salmeterol 59 CorVue ™ 59 REYATAZ ritonavir 59 nicardipine 59 adjunctive ABILIFY 59 atazanavir ritonavir 59 saline placebo 59 Lamictal XR 59 transdermal fentanyl 59 hemoglobin A1c HbA1c 59 hypomagnesemia 59 CPAP adherence 59 fasting plasma glucose 59 tolvaptan 59 pulmonary artery banding 59 rimonabant #mg/day 59 virologic failure 59 CANCIDAS 59 linaclotide treated 59 QTcF 59 #.#g/day 59 EXJADE 59 IBS symptoms 59 Secondary endpoints 59 remission CR 59 dosing cohort 59 analgesic medications 59 levetiracetam 59 mg eq 59 FROVA 59 FOSRENOL ® 59 octreotide LAR 59 rapid virologic response 59 gastrointestinal adverse reactions 59 levodopa therapy 59 rosuvastatin #mg 59 GnRH agonists 59 alfuzosin 59 alanine aminotransferase ALT 59 diarrhea flatulence 59 prodromal symptoms 59 transaminases 59 BENICAR 59 fasting plasma glucose FPG 59 3mg/kg 59 TLUS 59 laboratory abnormalities 59 HBeAg positive patients 59 paracentesis 59 ALVESCO 59 proctitis 59 ecchymosis 59 ACR# response 59 oral prednisone 59 mg Pycnogenol 59 interferon alfa 2b 59 AGILECT ® 59 acromegalic patients 59 INVEGA ® 59 β blocker 59 mg dose 59 #mg/m# [001] 59 REYATAZ r arm 59 TMC# r 59 placebo p 59 DAS# [002] 59 adalimumab 59 tolterodine 59 gout flare 59 urge incontinence 59 colesevelam HCl 59 Score DAS# 59 methacholine challenge 59 oral FTY# 59 receiving INTRON 59 candesartan cilexetil 59 epigastric pain 59 Baseline characteristics 59 hyperphenylalaninemia HPA due 59 oral diclofenac 59 opioid analgesia 59 lipid parameters 59 IFN alfa 59 primary efficacy endpoints 59 μg kg 59 MoxDuo IR 59 postintervention 59 CDAI score 59 virological response 59 SYMBICORT pMDI 59 vecuronium 59 YMRS 59 REMINYL ® 59 dosing intervals 58 ARB telmisartan 58 tegaserod 58 IOP lowering 58 inhalations twice 58 CrCl 58 baseline HbA1c 58 systemic corticosteroid 58 pentoxifylline 58 arthralgias 58 continuous intravenous infusion 58 frequent awakenings 58 abacavir lamivudine 58 clobazam 58 #mg doses [002] 58 Rating Scale MADRS 58 Pharmacokinetic parameters 58 antiemetics 58 trastuzumab Herceptin ® 58 mg simvastatin 58 ARIXTRA 58 postprocedure 58 teriflunomide 58 nausea somnolence 58 ribavirin RBV 58 nab paclitaxel 58 achieved CCyR 58 divalproex sodium 58 calculated creatinine clearance 58 CI -#.# 58 valacyclovir 58 ibandronate 58 ATACAND 58 lispro 58 rFSH 58 GERD symptoms 58 severe neutropenia 58 BENICAR HCT 58 FOLPI regimen 58 MIRAPEX 58 HbA1C levels 58 diarrhea predominant IBS 58 conjunctival hyperemia 58 dose cohort 58 Acetate Rectal Suppositories 58 relapsed MM 58 mg Proellex 58 creatinine clearance 58 dose proportional pharmacokinetics 58 knee osteoarthritis OA 58 postmenopausal osteoporotic women 58 progression TTP 58 deep venous thromboses 58 oxcarbazepine 58 ropinirole 58 FluCAM 58 achieved PASI 58 intermittent dosing 58 myopathy rhabdomyolysis 58 peginterferon 58 #mg QD [002] 58 β blockers 58 HbA1c levels 58 NATRECOR R 58 ribavirin therapy 58 peg IFN 58 placebo 58 quetiapine XR 58 atrioventricular block 58 International Prostate Symptom 58 dysmenorrhea 58 #mg dose [001] 58 paliperidone palmitate 58 clinically meaningful improvements 58 reflux symptoms 58 #μg [002] 58 Severity Index PASI 58 #mg dose [002] 58 prednisone prednisolone plus 58 EDSS score 58 Oral corticosteroids 58 hip BMD 58 cilostazol 58 tapentadol IR 58 hepatic metastases 58 GI motility 58 statistically significant superiority 58 piperacillin tazobactam 58 hematological parameters 58 fluticasone furoate 58 episodic migraine 58 recurrent genital herpes 58 odanacatib 58 ZOMIG Nasal Spray 58 events AEs 58 posaconazole 58 abdominal discomfort bloating 58 Q2W 58 clinically meaningful improvement 58 clomipramine 58 balsalazide 58 Traficet EN 58 HBV DNA levels 58 primary efficacy endpoint 58 weekly subcutaneous injections 58 hemoglobin A1c levels 58 placebo controlled studies 58 Viread Emtriva 58 upper gastrointestinal bleeding 58 clopidogrel Plavix 58 activated partial thromboplastin 58 serum clusterin levels 58 nasopharyngitis headache 58 EUFLEXXA R 58 potent CYP#A# inhibitors 58 GnRH agonist 58 intravenous bisphosphonates 58 postdose 58 QTc intervals 58 QTc interval 58 bleeding pallor 58 VIIBRYD 58 mg kg dose 58 sumatriptan naproxen sodium 58 Pegasys ® 58 diarrhea predominant irritable 58 metabolic parameters 57 CR nPR 57 dosing frequency 57 MYCAMINE 57 secondary endpoint 57 dyspnea 57 SGPT 57 Betaferon R 57 plasma uric acid 57 diabetic neuropathic pain 57 OADs 57 PREZISTA ritonavir 57 eculizumab therapy 57 creatinine ratio 57 Mg Uk 57 racemic albuterol 57 placebo controlled clinical trials 57 PEGINTRON TM 57 nonoperative treatment 57 serum aminotransferase levels 57 aplindore 57 phonophobia 57 Hamilton Anxiety Scale 57 placebo p = 57 â ‰ ¥ 57 gadolinium enhancing lesions 57 sulfasalazine 57 hematologic parameters 57 APIDRA R 57 receiving VICTRELIS 57 Neuropsychiatric Inventory NPI 57 headache abdominal pain 57 Thal Dex 57 dexmedetomidine 57 transaminase elevations 57 corticosteroid therapy 57 aspartate aminotransferase AST 57 icatibant 57 mg doses 57 overactive bladder symptoms 57 mL/min/#.# m2 57 intra articular 57 antiarrhythmic drug 57 ACTEMRA 57 dizziness nausea diarrhea 57 sufentanil 57 INCB# [003] 57 blood Phe levels 57 weekly intravenous infusions 57 ARICEPT 57 pravastatin therapy 57 aspirin clopidogrel 57 PCWP 57 Engerix B 57 1mg dose 57 GAMMAGARD 57 insulin degludec 57 zoledronate 57 definite stent thrombosis 57 BPH symptoms 57 paliperidone ER 57 COMBIVIR 57 ACR# ACR# 57 elagolix 57 hypokalemia 57 Natalizumab 57 Peg IFN 57 intravitreal injection 57 titrated glipizide 57 receiving golimumab 57 oral corticosteroids 57 miconazole 57 Lucentis monotherapy 57 postop 57 lacosamide 57 RAPAFLO R 57 mg ustekinumab 57 left ventricular diastolic 57 FOLFIRI 57 SCIg 57 OGTT 57 Zometa hazard 57 ocular inflammation 57 ACR# responses 57 serum uric acid 57 RAPTIVA 57 antiretroviral naive 57 placebo controlled trials 57 TURBT 57 NIH CPSI 57 ocular adverse 57 mg d 57 Sandostatin ® 57 gastric pH 57 IU mL 57 doxorubicin cyclophosphamide 57 low dose cytarabine 57 Keppra XR 57 eszopiclone 57 myoclonus 57 DETROL LA 57 Lantus ® 57 mcg mL 57 Scale EDSS 57 q#h 57 CRp 57 HoLEP 57 PSA nadir 57 Scale EDSS score 57 rimonabant #mg 57 biphasic insulin aspart 57 Keppra R 57 COPD exacerbation 57 Visual Analog Scale 57 IM progesterone 57 GSK# [001] 57 corrected QT interval 57 discontinuations due 57 mcg albinterferon alfa 2b 57 endometrial hyperplasia 57 intravenous iv 57 primary hypercholesterolemia 57 PEGylated anti 57 RHUCIN 57 paresthesias 57 antimuscarinic 57 H2 receptor antagonists 57 PEG Intron 57 μg dose 57 detrusor 57 QTc 57 intraocular inflammation 57 QD dosing 57 onset seizures 57 QT intervals 57 resolves spontaneously 57 pooled comparator 57 Visual Analogue Scale VAS 57 subcutaneously administered 57 rt PA 57 extrapyramidal disorder 57 ACR Pedi 57 menstrual bleeding 57 WOMAC pain 57 dose Qnexa 57 intra articular injections 57 DPNP 57 Gabapentin GR 57 HAM D# scores 57 symptomatic VTE 57 azelastine 57 DAPT 57 anagrelide 57 dysuria 57 apnea hypopnea 57 intra articular injection 57 LATUDA 57 PRADAXA #mg 57 hyaluronic acid fillers 57 #mg BID [002] 57 subcutaneous dose 57 oral anticoagulation 57 AVODART 57 serum HBV DNA 57 -#.# mg dL [002] 57 pretreatment baseline 57 esomeprazole 57 clodronate 57 Unified Parkinson Disease 57 cefazolin 57 Hypersensitivity reactions 57 Flu Cy 57 titration phase 57 unfractionated heparin UFH 57 vitreous floaters 57 subcutaneous infusion 57 nortriptyline Pamelor 57 LPV r 57 triamcinolone 57 zonisamide SR 57 IIIa inhibitor 57 cytogenetic responses 57 rotigotine 57 chemoradiation therapy 57 serum phosphate levels 57 epoetin alpha 57 #mg q8h 57 rituximab Rituxan ® 56 nasopharyngitis 56 mg BID dose 56 nausea constipation 56 primary generalized tonic 56 dose escalation phase 56 Fibromyalgia Impact Questionnaire 56 intravesical 56 concomitant medications 56 trospium 56 transurethral resection 56 salmeterol inhalation powder 56 somatostatin analog 56 prostate TURP 56 atorvastatin #mg 56 tipranavir 56 Index CDAI score 56 dose colchicine 56 log# IU mL 56 paclitaxel eluting stents 56 T2 lesions 56 intravenous diuretics 56 antiandrogen 56 plus prednisone prednisolone 56 response CCyR 56 anti androgen 56 laxation 56 eosinophilic asthma 56 dyspnoea 56 ZP PTH 56 glatiramer acetate 56 methotrexate monotherapy 56 DEXILANT 56 Postoperative 56 lumbar spine bone 56 ascending doses 56 cEVR 56 Solid Tumors criteria 56 UPDRS motor 56 composite endpoint 56 highly emetogenic 56 Cladribine tablets 56 ABC/3TC 56 alanine aminotransferase 56 liver biopsies 56 IFN α 56 annualized relapse 56 perineal pain 56 hepatic enzymes 56 plus MTX 56 VIRAMUNE XR 56 preintervention 56 interferon alfa 2a 56 -#.# ± [002] 56 dosage regimen 56 haematologic 56 MACUGEN 56 plus ribavirin 56 TDF FTC 56 inguinal hernia repair 56 hematologic toxicity 56 angiographic outcomes 56 diabetic gastroparesis 56 imipenem 56 CORDAPTIVE 56 serum phosphorus 56 HDRS 56 endoscopic remission 56 oral ribavirin 56 dopaminergic therapy 56 Non inferiority 56 ug dose 56 complete cytogenetic 56 oral antidiabetes drugs 56 T2 lesion volume 56 pCR 56 nerve conduction velocity 56 pioglitazone HCl 56 biochemical relapse 56 H2RAs 56 Insulin PH# 56 AGHD 56 dalteparin 56 Brief Psychiatric 56 PANSS scores 56 secondary efficacy endpoint 56 SSRI citalopram 56 pegylated interferon alfa 56 REYATAZ r 56 ADCS CGIC 56 Pegasys plus Copegus 56 mg/m2/day 56 PROCTOCORT ® Suppository Hydrocortisone 56 recombinant follicle stimulating 56 #μg [001] 56 mTSS 56 efalizumab 56 postoperatively 56 somnolence dizziness 56 LEXIVA 56 titrated 56 hemorrhagic complications 56 pneumonectomy 56 tamoxifen Nolvadex ® 56 INFERGEN 56 menopausal symptom 56 -#.# log# copies mL 56 ritonavir boosted atazanavir 56 dysmenorrhoea 56 ULORIC 56 deferasirox 56 recurrent glioblastoma multiforme 56 copies mL 56 dose cohorts 56 sonographically guided 56 MCyR 56 carotid endarterectomy CEA 56 prolonged QT interval 56 tenofovir emtricitabine 56 oral iron chelator 56 oral vancomycin 56 intravenous cyclophosphamide 56 macroalbuminuria 56 ascending dose 56 adenotonsillectomy 56 Aptivus ® 56 glycated hemoglobin levels 56 oral ibandronate 56 trough FEV1 56 thorough QT 56 invasive aspergillosis 56 Aloxi injection 56 fatigue abdominal pain 56 concomitant AEDs 56 CNS LS 56 mg FV 56 herpetic keratitis 56 dose regimens 56 dactylitis 56 bupropion SR 56 Lipitor #mg 56 prespecified secondary 56 thromboprophylaxis 56 subcutaneous doses 56 subcutaneous dosing 56 verum acupuncture 56 reintubation 56 Navelbine 56 alicaforsen enema 56 liver histology 56 -#.# log# 56 forodesine 56 Dextofisopam 56 locomotor activity 56 mg q8h 56 oxybutynin 56 TOVIAZ 56 FOLFOX4 56 oral methylnaltrexone 56 acarbose 56 5mg/kg 56 nucleoside naive 56 F FDG PET 56 hour bronchodilation 56 Virologic 56 nasal obstruction 56 #:# randomization 56 aminotransferases 56 PEG Intron ® 56 retropubic 56 antiepileptic drugs AEDs 56 symptomatic hyponatremia 56 liposome injection 56 urinary symptoms 56 fluoxetine paroxetine 56 IBDQ 56 elevated ALT 56 BROVANA 56 mcg dose 56 antiplatelet drugs 56 Infusion Reactions Severe 56 MIRAPEX ER 56 Score TOS 56 INC# 56 Durezol 56 BARACLUDE ® 56 P = .# 56 generalized tonic clonic seizures 56 cystoscopic 56 mL kg 56 treatment emergent adverse 56 antiplatelet medication 56 alteplase 56 albiglutide 56 aspartate aminotransferase 56 log# 56 oral prednisolone 56 experienced virologic failure 56 reduce serum phosphate 56 ZYVOX 56 histrelin 56 RoACTEMRA 56 mg tid 56 painful menstruation 56 buprenorphine naloxone 56 cerebrovascular events 56 secondary efficacy endpoints 56 VIRAMUNE 56 lymphadenectomy 56 CLARITY study 56 MULTAQ 56 mg dosed once 56 VA# [002] 56 octreotide acetate 56 pegylated interferon alpha 56 bosentan 56 non constipation irritable 56 acute HAE attacks 56 antibiotic prophylaxis 56 estimated glomerular filtration 56 baseline A1C 56 nevirapine Viramune 56 methacholine 56 metabolic alkalosis 56 virologic responses 56 PRADAXA 56 Score DAS 56 mcg kg REBETOL 56 5-FU/LV 56 hypogonadal men 56 MADRS 56 severe renal impairment 56 venlafaxine ER 56 glycoprotein IIb IIIa inhibitor 56 pyrazinamide 56 daily subcutaneous injections 56 postoperative AF 56 colorectal liver metastases 56 mineral density BMD 56 PEGINTRON 56 PFPS 55 angioplasty stenting 55 bolus dose 55 conjugated estrogens 55 NIHSS 55 oral allopurinol 55 esophagogastric 55 FIRMAGON 55 Vimpat R 55 Naive Patients 55 inactive placebo 55 Tolvaptan 55 treprostinil 55 pregabalin 55 diuretic chlorthalidone 55 placebo controlled clinical 55 octreotide 55 chest radiographs 55 oral amoxicillin 55 R# #mg BID 55 treatment emergent AEs 55 chlorambucil 55 Montgomery Åsberg Depression 55 intramuscular injections 55 glycosylated hemoglobin HbA1c 55 TURP 55 ABILIFY Injection 55 HBeAg negative 55 ORENCIA ® 55 azilsartan medoxomil 55 incidence ≥ 55 glycoprotein IIb IIIa inhibitors 55 paricalcitol 55 8mg 55 peginterferon alfa 2b 55 insulin lispro 55 R brand eszopiclone 55 #mg/m# [002] 55 avosentan 55 pharyngolaryngeal pain 55 tiotropium bromide 55 cinacalcet 55 mealtime insulin 55 detrusor overactivity 55 constipation OIC 55 biologic DMARD 55 glargine 55 HCV RNA 55 Veramyst 55 DMARD therapy 55 ULN 55 glycated hemoglobin HbA1c 55 genotypic resistance 55 deferoxamine 55 FOSRENOL R 55 generalized anxiety disorder GAD 55 acute gout flares 55 IPSS 55 intradermal injections 55 ADAS cog 55 HPA axis suppression 55 statistically significant p 55 anterior uveitis 55 everolimus eluting stents 55 neutropenia thrombocytopenia 55 Detrol Detrol LA 55 Sprycel dasatinib 55 postsurgical pain 55 Lubiprostone 55 ZOLINZA 55 mitoxantrone plus 55 oral olanzapine 55 erythrocyte sedimentation rate 55 flutamide 55 nocturnal hypoglycaemia 55 LYSTEDA 55 pramlintide metreleptin combination 55 methotrexate therapy 55 CYPHER R Sirolimus eluting 55 plasma creatinine 55 proton MR spectroscopy 55 aPTT 55 Focalin XR 55 GOUT 55 severe hypoglycemic 55 achieved sustained virologic 55 pegylated interferon alfa 2b 55 HIV RNA 55 abdominal circumference 55 HAMD 55 inhaled budesonide 55 Pred Forte 55 Platelet counts 55 LAB GHRH 55 FDA defined valvulopathy 55 safinamide 55 neuroleptics 55 treatment naive genotype 55 XEPLION R 55 denervation 55 #mg dosing group 55 protease inhibitor PI 55 bronchodilation 55 -#.# mg dL [001] 55 PANSS 55 serologically active patients 55 epidural steroid injections 55 Negative Syndrome 55 colorectal adenoma 55 FOLFIRI alone 55 Score IPSS 55 NATRECOR ® 55 beclomethasone dipropionate 55 APTIVUS ritonavir 55 FOLFOX6 55 bezafibrate 55 transthoracic 55 PREZISTA r arm 55 idraparinux 55 UPDRS 55 osteoporotic vertebral compression fractures 55 #mg/kg [002] 55 aldosterone antagonist 55 radicular pain 55 RSD# oral 55 superficial bladder cancer 55 Randomized Double Blind 55 golimumab CNTO 55 overactive bladder OAB 55 serum testosterone 55 Tasigna prolongs 55 symptomatic BPH 55 tiotropium 55 PSADT 55 FOLFOX 55 serum concentrations 55 bupivacaine 55 serum urate levels 55 ALND 55 plasma HCV RNA 55 dapagliflozin plus 55 achieved mucosal healing 55 hypophosphatemia 55 pramipexole 55 APTIVUS 55 plasma glucose 55 macrolide antibiotic 55 hepatectomy 55 XOPENEX HFA 55 relapsing remitting MS RRMS 55 RECIST criteria 55 mL/min/#.# m 2 55 DAS# CRP 55 GLIADEL R Wafer 55 Ophena TM